Spectrofluorometric Analysis of New-Generation Antidepressant Drugs in Pharmaceutical Formulations, Human Urine, and Plasma Samples

Table 4

Recovery studies of analytes in pharmaceutical preparations by proposed method.

Pharmaceutical preparation	Amount added	Found^1 (ng/μL)	(%) RE^2	(%) Recovery^3±
	(ng/μL)	± SD^1		RSD
SER (Tab)	10	08.95±0.123	10.5	89.50±2.65
	50	49.98±0.126	0.04	99.96±3.17
	100	100.02±0.065	0.02	100.02±4.53
PAR (Tab)	10	10.02±0.312	0.20	102.0±2.86
	50	48.89±0.256	2.22	97.78±3.53
	100	98.72±0.146	1.28	98.72±5.16
CIT (Tab)	10	09.88±0.083	1.20	98.80±1.63
	50	48.88±0.192	2.24	97.76±3.78
	100	98.68±0.102	1.32	98.68±4.84
VLF (Tab)	10	08.78±0.350	12.2	87.80±1.58
	50	47.35±0.048	5.30	94.70±3.12
	100	96.01±0.028	3.99	96.01±4.54
FLX (Tab)	10	08.66±0.034	15.4	86.60±2.13
	50	48.85±0.058	2.30	97.70±4.89
	100	97.89±0.283	2.11	97.89±5.15

¹Average of six determinations; ²accuracy (% error) = amount found – amount added/added×100, ³recovery of amount added to the pharmaceutical formulation (average of six determinations).